Oracle

In a recent virtual roundtable discussion, industry experts Jim Streeter, Alison Holland, Hassan Kadhim, Craig Lipset, Josh Rose, and Craig Serra shared their insight on the challenges faced in implementing decentralized trials and how to address them. Along with the roundtable are video discussions covering the cost and feasibility of a toolkit approach to decentralized trials, the significance of minimizing burden to patients and sites, and the reality of regulatory hurdles.

Virtual elements in clinical trials require extra considerations All teams involved should maintain ongoing dialogue and collaboration for success A discussion with industry leaders provides insight into such trials

- Clinical trials can be designed across a continuum of formats. - Adding decentralized elements to trials can help acquire high-quality data. - Sponsors must understand the impact across the trial landscape for success.